JAN 22, 2021 8:17 PM PST

Treating NF1: Investigational Drug Shows Positive Results

WRITTEN BY: Nouran Amin

From preclinical studies, researchers have found that an investigational drug called ‘cabozantinib’ can treat tumors form a genetic disorder known as neurofibromatosis type 1 (NF1).

"This is the second class of drugs to demonstrate a very promising response rate for NF1 patients with these tumors," said first author Fisher, Chief of the Section of Neuro-Oncology and Director of the Neurofibromatosis Program at CHOP, and Group Chair for the NF Clinical Trials Consortium, which includes 25 sites developing innovative biologically-based clinical trials for complications of NF. "Collectively, the data presented in this study illustrate a true bench-to-bedside approach, coordinating translational and clinical efforts to advance targeted therapies for a rare disease like NF1."

NF1 is a rare disease affecting approximately 1 in 3000 people globally and is characterized by a proliferation of tumors throughout the nervous system.

Learn more about NF1:

"It's incredibly exciting that we now have two classes of drugs that result in tumor responses, given that we had no promising agents only a few years ago," Dr. Fisher said. "However, despite this excitement, neither cabozantinib nor MEK inhibitors shrink all tumors or make them go away completely. Therefore, we are building on these results as well as ongoing laboratory studies and are planning future exploration of combination therapies, so that we can further improve outcomes for these patients with these debilitating and life-threatening tumors."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
NOV 25, 2020
Immunology
The History of Vaccines
NOV 25, 2020
The History of Vaccines
Everyone worldwide is sitting with anticipation, waiting for the right vaccine candidate for the coronavirus outbreak, h ...
DEC 18, 2020
Drug Discovery & Development
Lab-Induced Hallucinations Could Help Develop New Drugs
DEC 18, 2020
Lab-Induced Hallucinations Could Help Develop New Drugs
Researchers from the University of New South Wales in Australia have found that inducing hallucinations in healthy subje ...
DEC 18, 2020
Drug Discovery & Development
Antibiotic Reduces Risk of Deafness
DEC 18, 2020
Antibiotic Reduces Risk of Deafness
Gentamicin is an antibiotic recently shown to reduce the risk of developing deafness according to a Stanford Medicine st ...
JAN 27, 2021
Drug Discovery & Development
Researchers Discover How LSD Encourages Prosocial Behavior
JAN 27, 2021
Researchers Discover How LSD Encourages Prosocial Behavior
Researchers from McGill University have discovered one of the possible mechanisms by which lysergic acid diethylamide (L ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
Loading Comments...